Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Votre recherche
Pays: Korea, Republic of,Israel,United States,Australia,Spain,Germany,Italy,Taiwan, Province of China
nct
MAJ Il y a 5 ans
Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
Primary To evaluate the efficacy of satavaptan on top of diuretic drugs in reducing the recurrence of ascites. Secondary To evaluate the tolerability and safety of satavaptan on top of diuretic drugs over a 52-week treatment period in participants with cirrhosis of the liver and recurrent ascites. The one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (PASCCAL-2).
Pays
Argentina
,
Australia
,
Belgium
,
Bosnia and Herzegovina
,
Bulgaria
,
Canada
,
Croatia
,
Czech Republic
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Korea, Republic of
,
Malaysia
,
Portugal
,
Romania
,
Serbia
,
Singapore
,
South Africa
,
Spain
,
Taiwan, Province of China
,
United Kingdom
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma
The primary purpose of this study is to see how tasisulam affects metastatic melanoma when compared against paclitaxel as measured by overall survival.
Pays
Australia
,
Austria
,
Belgium
,
Canada
,
Finland
,
France
,
Germany
,
Israel
,
Italy
,
Korea, Republic of
,
Netherlands
,
Norway
,
Poland
,
Spain
,
Sweden
,
Taiwan, Province of China
,
United Kingdom
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
nct
MAJ Il y a 5 ans
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
To compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.
Pays
Australia
,
China
,
Colombia
,
Czech Republic
,
Denmark
,
France
,
Germany
,
Greece
,
Ireland
,
Israel
,
Italy
,
Korea, Republic of
,
Malaysia
,
Mexico
,
Poland
,
Slovakia
,
Spain
,
Sweden
,
Switzerland
,
Taiwan, Province of China
,
United Kingdom
,
United States
,
Organes
Aucun
Spécialités
Aucun
Essai clos aux inclusions
Plus d'informations
1